Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 8, 2005, Pages 3317-3324

  Seibel, Nita L ^a   Schwartz, Cindy ^b   Arrieta, Antonio ^c   Flynn, Patricia ^d   Shad, Aziza ^e   Albano, Edith ^f   Keirns, James ^g   Lau, Wendi M ^g   Facklam, David P ^g   Buell, Donald N ^g   Walsh, Thomas J ^h  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^f CHILDREN S HOSPITAL   (United States)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICAFUNGIN;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SEPTIC SHOCK; VOMITING;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; FEMALE; FEVER; HUMANS; LIPOPROTEINS; MALE; MYCOSES; NEUTROPENIA; PEPTIDES, CYCLIC; TREATMENT OUTCOME;

EID: 23044445767     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.8.3317-3324.2005     Document Type: Article

References (28)

1. Abassi, S., J. L. Shenep, W. T. Hughes, and P. M. Flynn. 1999. Aspergillosis in children with cancer: a 34-year experience. Clin. Infect. Dis. 29:1210-1219.
2. Chanock, S. J., and T. J. Walsh. 1996. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. Bone Marrow Transpl. 18(Suppl. 3):S15-S20.
3. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
4. Gatta, G., R. Capocaccia, M. P. Coleman, L. A. G. Ries, and F. Berrino. 2002. Childhood cancer survival in Europe and the United States. Cancer 95:1767-1772.
5. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 409-416. Marcel Dekker, Inc., New York, N.Y.
6. Groll, A. H., M. Kurz, W. Schneider, V. Witt, H. Schmidt, M. Schneider, and D. Schwabe. 1999. Five-year survey of invasive aspergillosis in a pediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 42:431-442.
7. Groll, A. H., D. Mickiene, V. Petraitis, R. Petraitiene, K. H. Ibrahim, S. C. Piscitelli, I. Bekersky, and T. J. Walsh. 2001. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin-like lipopeptide FK463 in rabbits. Antimicrob. Agents Chemother. 45:3322-3327.
8. Groll, A. H., and T. J. Walsh. 2000. Evaluation of the antifungal echinocandin FK463. Curr. Opin. Investig. Drugs 2:405-412.
9. Groll, A. H., and T. J. Walsh. 2003. Fungal infections in pediatric patients, p. 417-422. In M. McGinnis, M. Pfaller, and E. Anaissie (ed.), Clinical mycology. Churchill Livingstone, Philadelphia, Pa.
10. Groll, A., and T. J. Walsh. 2003. Antifungal agents, p. 3075-3108. In R. D. Feigin, J. D. Cherry, G. J. Demmler, and S. L. Kaplan (ed.), Textbook of pediatric infectious diseases.
11. Harris, R. E., H. N. Sather, and S. A. Feig. 1998. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience. Med. Pediatr. Oncol. 30:233.
12. Hatano, K., Y. Morishita, T. Nakai, and F. Ikeda. 2002. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J. Antibiot. 55:219-222.
13. Hayes-Lattin, B., and R. T. Maziarz. 2004. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. Leuk. Lymphoma 45:669-680.
14. Hovi, L., U. Saarinen-Pihkala, K. Vettenranta, and H. Saxen. 2000. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 26:999-1004.
15. Ikeda, F., Y. Wakai, S. Matsumoto, K. Maki, E. Watabe, S. Tawara, T. Goto, Y. Watanabe, F. Matsumoto, and S. Kuwahara. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. 44:614-618.
16. Lee, J. W., N. I. Seibel, M. A. Amantea, P. Whitcomb, P. A. Pizzo, and T. J. Walsh. 1992. Safety, tolerance, and pharmacokinetics of fluconazole in children with neoplastic diseases. J. Pediatr. 120:987-993.
17. Matsumoto, S., Y. Wakai, T. Nakai, K. Hatano, T. Ushitani, F. Ikeda, S. Tawara, T. Goto, F. Matusumoto, and S. Kuwahara. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob. Agents Chemother. 44:619-621.
18. Mikamo, H., Y. Sato, and T. Tamaya. 2000. In vitro antifungal activity of FK463, a new water soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother. 46:485-487.
19. Petraitis, V., R. Petraitiene, A. H. Groll, K. Roussillon, M. Hemmings, C. A. Lyman, T. Sein, J. Bacher, I. Bekersky, and T. J. Walsh. 2002. Comparative antifungal activity and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 46:1857-1869.
20. Pettengell, K., J. Mynhardt, T. Kluyts, W. Lau, D. Facklam, and D. Buell. 2004. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment. Pharmacol. Ther. 20:475-481.
21. Tawara, S., F. Ikeda, K. Maki, Y. Morishita, K. Otomo, N. Teratani, T. Goto, M. Tomishima, H. Ohki, A. Yamada, K. Kawabata, H. Takasugi, K. Sakane, H. Tanaka, F. Matsumoto, and S. Kuwahara. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44:57-62.
22. Tukey, J. W. 1977. Exploratory data analysis, p. 43-45. Addison-Wesley, Reading, Mass.
23. van Burik, J.-A., V. Ratanatharathorn, D. E. Stepan, C. B. Miller, J. H. Lipton, D. H. Vesole, N. Bunin, D. A. Wall, J. W. Hiemenz, Y. Satoi, J. M. Lee, and T. J. Walsh for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39: 1407-1416.
24. Walsh, T. J., P. C. Adamson, N. L. Seibel, P. M. Flynn, M. N. Neely, C. Schwartz, A. Shad, S. Kaplan, M. M. Roden, J. A. Stone, A. Miller, S. K. Bradshaw, S. X. Li, C. A. Sable, and N. A. Kartsonis. An open-label, sequential dose-escalation study to investigate the pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother., in press.
25. Walsh, T. J., M. O. Karlsson, T. Driscoll, A. G. Arguedas, P. Adamson, X. Saez-Llorens, A. J. Vora, A. C. Ariettas, J. Blumer, I. Lutsar, P. Milligan, and N. Wood. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-2172.
26. Wiley, J. M., N. Smith, B. G. Leventhal, M. L. Graham, L. C. Strauss, C. A. Hurwitz, J. Modlin, D. Mellits, R. Baumgardner, and B. J. Corden. 1990. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J. Clin. Oncol. 8:280-286.
27. Wingard, J. R., W. P. Vaughan, H. G. Braine, W. G. Merz, and R. Saral. 1987. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am. J. Med. 83:1103-1110.
28. Xie, Y., S. M. Davies, Y. Xiang, L. L. Robison, and J. A. Ross. 2003. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 97:2229-2235.